DON'T LET RETAINED BLOOD SYNDROME BLOCK YOUR PATIENT'S RECOVERY

FLOW BETTER
WITH PLEURAFLOW® ACTIVE CLEARANCE TECHNOLOGY®
A recent prospective study found that 36% of patients suffer from completely blocked chest tubes. Worse yet, 86% of those occlusions were intra-thoracic and therefore invisible to the bedside caregivers. The crucial hours post-surgery, when the patient is still bleeding, are vitally important. Why risk patient outcomes by relying on a conventional chest tube to evacuate blood from the surgical site?

Blocked chest tubes can lead to Retained Blood Syndrome (RBS) – the composite of drainage-related post-cardiothoracic surgery complications that are detrimental to patient outcomes and may require early or late reinterventions.

Retained Blood Syndrome (RBS) causes multiple mechanical and inflammatory complications that may lead to additional interventions and readmissions. These complications can occur at any stage of recovery and may include hemothorax, pericardial tamponade, and bloody pleural or pericardial effusions.

Patient outcomes and healthcare costs are negatively impacted by RBS.

Unreimbursable Costs Per Patient with RBS

- **COST OF CARE**: $28,814 per RBS
- **LENGTH OF STAY**: 5.8 days Increase
- **MORTALITY RATE**: doubled 3% to 6%

36% of chest tubes block completely

17% of patients require one or more reinterventions due to RBS
PROTECT PATIENTS FROM RBS

with PleuraFlow® Active Clearance Technology® (ACT™) System

Developed by cardiac surgeons, PleuraFlow ACT is a unique system that proactively prevents or minimizes chest tube occlusions and reduces retained blood - a known contributor to POAF and other RBS complications which can increase length of stay (LOS), mortality rates, and hospital readmissions.3,5

The PleuraFlow System has been shown to reduce the incidence of RBS by 43% and POAF by 33%.5

In a recent peer-reviewed study in the Journal of Thoracic and Cardiovascular Surgery (JTCVS), PleuraFlow ACT was reported to:

• Reduce Retained Blood Syndrome (RBS) reinterventions from 20% to 11% (a 43% reduction, p=0.0087)
• Reduce Post-operative Atrial Fibrillation (POAF) from 30% to 20% (a 33% reduction, p=0.013)

Minimize Patient Discomfort

Our 20FR PleuraFlow ACT System removes nearly triple the amount of blood than a traditional 32FR drain (525 ml vs. 183 ml) and your patients may benefit from a smaller and more flexible silicone tube.6
ACT NOW

Improve Outcomes, Lower Costs

Ordering Information

PleuraFlow® ACT™ Systems
All Systems include a straight silicone chest tube and a clearance apparatus.

<table>
<thead>
<tr>
<th>CODE</th>
<th>SIZE</th>
<th>EFFECTIVE-DRAINAGE LENGTH (EDL)</th>
<th>NUMBER OF EYELETS</th>
</tr>
</thead>
<tbody>
<tr>
<td>PF-20</td>
<td>20FR</td>
<td>4” (10.2 cm)</td>
<td>6</td>
</tr>
<tr>
<td>PF-24</td>
<td>24FR</td>
<td>4” (10.2 cm)</td>
<td>6</td>
</tr>
<tr>
<td>PF-28</td>
<td>28FR</td>
<td>4” (10.2 cm)</td>
<td>6</td>
</tr>
<tr>
<td>PF-32</td>
<td>32FR</td>
<td>4” (10.2 cm)</td>
<td>6</td>
</tr>
</tbody>
</table>

Exclusively distributed in the US by Maquet Medical Systems USA.
www.maquetusa.com

References

2. Based on over 313,000 US adult heart surgery patients. Data extracted using ICD-9 codes from the 2010 Nationwide Inpatient Sample (NIS), from the DHHS Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project (HCUP).


ML004-J

Copyright © 2016 ClearFlow, Inc. All Rights Reserved.

Trademark and Registered Trademarks of ClearFlow, Inc.


US FDA 510(k): K150042; Health Canada License Number 92263; ARTG Identifier 218317; CE Marking Registration Number: 252.1078

Manufactured For:
ClearFlow, Inc.
1630 S. Sunkist St., Suite E
Anaheim, CA, US, 92806
www.clearflow.com

EU Authorized Representative:
Emergo Europe
Molenstraat 15
2513 BH. The Hague
The Netherlands